Patient-derived xenografts, or PDX models, involve the implantation of human tumor tissues directly into immunodeficient mice. These models maintain the histological architecture and genetic makeup of the original tumors far better than traditional cell lines, offering a more clinically relevant arena for testing therapeutic agents. The Chinese research team capitalized on this technique by transplanting over 1,000 surgical and biopsy specimens from patients with various gastrointestinal malignancies, including ESCC, esophagogastric junction adenocarcinoma (EGJAC), and gastric adenocarcinoma (GAC), into NOD/SCID mice, which lack adaptive immunity.

Between January 2013 and August 2015, the researchers conducted a comprehensive engraftment campaign, implanting the fresh tumor tissues subcutaneously into specialized mice and meticulously documenting engraftment rates and tumor growth dynamics. A total of 208 xenograft models were successfully established, representing an overall engraftment rate of approximately 20.8%, a notable achievement given the inherent challenges in PDX formation, especially within gastrointestinal tumors renowned for their heterogeneity and aggressive nature.

Diving deeper into the types of cancers, ESCC exhibited the highest engraftment rate at 21.2%, substantiating its clinical significance within the Chinese demographic due to higher incidence rates. EGJAC and GAC followed with engraftment rates of 16.9% and 10.9%, respectively. These variances underscore the biological complexities and tumor microenvironment interactions unique to each cancer subtype, influencing successful xenografting.

The latency period, or the time taken for implanted tumors to grow sufficiently in mice, varied amongst the cancer types. For the initial passage, ESCC xenografts established within an average of approximately 76 days, whereas EGJAC and GAC showed longer latency periods of around 90 and 85 days, respectively. Interestingly, during the subsequent passage, these latency periods reduced significantly across all tumor types, averaging around 52 to 55 days. This observation suggests an adaptation process where tumor cells, once acclimatized to the murine environment, exhibit expedited growth kinetics in subsequent passages.

Beyond mere establishment rates, the study unearthed noteworthy correlations between clinical and pathological factors and successful engraftment. In ESCC cases, variables such as patient gender, the type of specimen (biopsy vs. surgical tissue), and tumor differentiation significantly influenced engraftment outcomes. In gastric adenocarcinoma, factors including patient age, specimen type, tumor differentiation, and Lauren classification—a histological subtype categorizing gastric tumors as intestinal or diffuse—played influential roles. Such nuanced understanding emphasizes the importance of patient and tumor characteristics in PDX success rates, potentially aiding future patient stratification for personalized models.

From a clinical perspective, the team monitored patients over extended periods—46 months for ESCC and 64 months each for EGJAC and GAC—shedding light on the prognostic implications of xenograft formation. Intriguingly, patients with gastric adenocarcinoma whose tumor tissues yielded successful xenografts showed significantly poorer survival compared to those whose tumors failed to engraft. This finding aligns with previous literature suggesting that aggressive tumor biology is more amenable to PDX establishment, thereby providing a dual opportunity to study both tumor aggressiveness and responsiveness.

The establishment of this Chinese PDX library holds immense promise beyond academic achievement. It offers a robust platform for preclinical drug evaluation that more faithfully mimics human tumor biology. By encompassing tumor types prevalent in the Chinese population, the repository addresses a significant gap in cancer research where most existing PDX models are derived from Western populations, potentially limiting translational applicability.

Moreover, this repository facilitates personalized oncology approaches by enabling drug sensitivity testing on patient-specific tumor models. This approach could refine treatment regimens and identify novel therapeutic targets, ultimately enhancing patient outcomes. The ability to predict clinical responses based on PDX testing could transform current cancer care paradigms from empirical treatment choices to biology-driven precision medicine.

Establishing and maintaining such a biobank require overcoming considerable technical and logistical challenges, including tissue procurement, handling, and engraftment consistency. The success rate reported in this study reflects rigorous methodological optimization and a sustained commitment to creating a high-quality resource. The researchers’ choice of NOD/SCID mice underscores the necessity of immunodeficient hosts to facilitate human tumor growth, eliminating confounding by host immune rejection.

As this PDX library expands, it opens avenues for collaborative research endeavors at both national and international levels. The availability of well-characterized, genomically annotated PDX models could accelerate the validation of molecular targets and the development of next-generation therapeutic agents tailored to tumor-specific vulnerabilities.

Furthermore, this initiative underscores the importance of integrating clinical annotations with experimental models. Matching PDX data with detailed patient clinical information enriches the translational value of findings and fosters the discovery of biomarkers predictive of treatment response or resistance.

While the current focus centers on gastrointestinal tumors—given their significant morbidity and mortality in China—the framework established by this research sets a precedent for creating PDX libraries from other cancer types, fostering a broader understanding of cancer heterogeneity and treatment resistance mechanisms.

In synthesizing these efforts, this study contributes substantially to the global oncology research infrastructure. It aligns with the growing consensus that high-fidelity preclinical models are paramount to overcoming the translational gap that has historically hindered effective drug development.

In conclusion, the establishment of a Chinese PDX library from gastrointestinal cancers signifies a milestone in personalized cancer research. By capturing the biological intricacies of predominant local tumor types, this resource empowers researchers and clinicians with refined tools for therapy development and individualized treatment decision-making. This endeavor not only enhances scientific understanding but also holds the potential to directly impact patient care, offering hope for improved survival outcomes in a cancer-burdened population.

Subject of Research: Establishment and characterization of a patient-derived xenograft (PDX) library from gastrointestinal cancers prevalent in China, including esophageal squamous cell carcinoma, esophagogastric junction adenocarcinoma, and gastric adenocarcinoma.

Article Title: Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers

Article References:
Liu, Y., He, W., Wu, Q. et al. Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers. BMC Cancer 25, 1508 (2025). https://doi.org/10.1186/s12885-025-14845-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14845-y

Over the past decade, PDX models have emerged as powerful surrogates for patient tumors, prized for preserving histological and genetic features. Yet, the metabolic landscape—an orchestra of biochemical reactions underpinning tumor growth and survival—has remained less clearly characterized. Metabolism is intimately tied to the cancer phenotype, influencing everything from proliferation to drug resistance. Hence, understanding how metabolic profiles evolve or stabilize during xenotransplantation is vital for ensuring experimental results mirror clinical reality. Rao et al. deliver a comprehensive comparative analysis, marrying metabolomics with transcriptomics, to illuminate this obscure frontier.

Central to the study is the use of matched pairs of patient tumors and respective PDXs, sourced from diverse cancer types. By leveraging mass spectrometry-based metabolite profiling alongside gene expression data, the researchers delineate the metabolic fingerprints of original tumors and their xenografted counterparts. This dual-omics approach enables a multidimensional understanding of metabolic regulation, extending beyond static metabolite measurements to encompass the dynamic control exerted by metabolic genes. The team employs sophisticated bioinformatic pipelines to discern patterns of metabolic conservation and divergence, setting a new standard for rigor in metabolic phenotyping.

One of the pivotal revelations from this work is that while a core subset of metabolic phenotypes remains remarkably conserved between patient tumors and PDX models, significant differences also emerge. Conserved pathways notably include central carbon metabolism aspects such as glycolysis and tricarboxylic acid (TCA) cycle activity, underscoring fundamental energetic programs essential for tumor viability. This conservation validates the continued use of PDX models for studying certain metabolic vulnerabilities—pathways universally co-opted by tumors regardless of microenvironmental context.

Contrastingly, the study reveals divergence in pathways linked to amino acid metabolism, lipid biosynthesis, and redox balance. These variations are hypothesized to stem from the distinct tumor microenvironment in the murine host, which differs drastically from human physiology in factors such as oxygen tension, nutrient availability, and stromal interactions. For example, alterations in cysteine and glutathione metabolism indicate shifts in oxidative stress responses, potentially reflecting adaptive rewiring to the xenograft’s niche. Such metabolic shifts complicate extrapolations from PDX data to the human clinical setting, signaling caution in interpreting results pertaining to metabolic drug targets.

The authors further delineate the influence of tumor intrinsic properties and external factors on metabolic fidelity. Tumors originating from different tissues exhibit variable degrees of metabolic stability post-engraftment, suggesting tissue-specific constraints and plasticity. Moreover, engraftment site and passage number impact metabolic phenotypes, with later PDX passages showing increased divergence likely due to clonal selection and ongoing adaptation. This insight underscores the dynamic nature of metabolic phenotypes and demands thoughtful experimental design when employing PDX models for metabolic investigations.

Intriguingly, although the immune-compromised murine environment simplifies immune-mediated confounders, it simultaneously removes complex human immune-tumor metabolic crosstalk. This absence likely contributes to the metabolic discrepancies observed, particularly in pathways involved in immune modulation and inflammation. Hence, the study raises critical questions about the limitations of existing PDX platforms for immunometabolic research and encourages the development of humanized models that better recapitulate tumor-immune dialogues.

The ramifications of this research extend into therapeutic realms. Metabolic reprogramming is a hallmark of many emerging anticancer strategies, yet if PDX models do not entirely mirror the original tumor’s metabolism, predictions of drug efficacy may be misleading. By identifying specific metabolic pathways that reliably translate between patient and model, the study offers a roadmap for prioritizing targets with higher translational fidelity. Conversely, pathways prone to divergence warrant validation in orthogonal systems before clinical extrapolation.

Technically, Rao et al. push the envelope by integrating high-resolution metabolomics with transcriptomic data in a paired-sample design—a strategy rarely implemented at this scale. Their statistical frameworks correct for batch effects and normalize for inter-sample variability, enhancing confidence in identified differences. This methodological rigor sets a precedent for future metabolic phenotype studies, emphasizing the necessity of multidimensional data integration to unravel complex biological phenomena.

The study also touches upon the potential influence of the host microbiome, an often-overlooked variable in PDX metabolism. While not the central focus, the authors speculate that interactions between murine gut flora and tumor metabolism could subtly shape observed phenotypes. This presents an intriguing extension for future research, as the microbiome’s role in modulating systemic metabolism and therapeutic responses gains broader recognition across oncology disciplines.

Furthermore, the findings invite reevaluation of the widely held dogma that PDX models fully capture patient tumor biology. While invaluable, the recognized metabolic remodeling suggests that PDX models represent a facet, rather than the entirety, of tumor metabolic reality. This reframing encourages complementary use of alternative models such as organoids, genetically engineered mouse models, and ultimately, patient-based clinical studies to triangulate tumor metabolism comprehensively.

Importantly, this work exemplifies the need for metabolic context awareness when interpreting experimental data. Simply put, the tumor ecosystem does not operate in isolation; it engages in continuous, reciprocal interactions with its environment. By highlighting environmental and evolutionary factors influencing metabolic phenotypes post-engraftment, the study underscores that metabolic traits are not immutable identifiers but plastic features subject to selective pressures.

The researchers also emphasize that their findings could influence biomarker discovery pipelines. Metabolites or gene signatures showing stable conservation across patient and PDX contexts represent promising biomarker candidates with higher predictive utility. Conversely, markers with inconsistent presence may reflect experimental artifacts or environmental adaptations, warranting cautious consideration.

Finally, Rao and colleagues’ work paves the way for refining PDX-based therapeutic screening by incorporating metabolic profiling as a standard evaluative layer. Such integrative approaches could enhance the predictive power of preclinical models, accelerating the translation of metabolic-targeted therapies from bench to bedside. It is a compelling call for the cancer research community to broaden their toolkit and adopt more holistic, systems-level assessments.

In sum, this landmark study charts new territory by systematically dissecting metabolic conservation and divergence in patient tumors and matched PDX models. It reveals a nuanced metabolic landscape shaped by both inherent tumor properties and extrinsic environmental factors. These insights provoke a paradigm shift, challenging assumptions about xenograft model fidelity and urging the field towards more sophisticated frameworks that appreciate tumor metabolism’s dynamic and context-dependent nature. As cancer metabolism continues to be a fertile ground for therapeutic innovation, studies like this will be indispensable guides for precision oncology’s future trajectory.

Subject of Research: Metabolic comparison between patient tumors and matched xenograft models.

Article Title: Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts.

Article References:
Rao, A.D., Cai, L., Snyman, M. et al. Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01338-2

Image Credits: AI Generated